Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells.
Chemotherapeutic agents and gamma-irradiation used in the treatment of brain tumors, the most common solid tumors of childhood, have been shown to act primarily by inducing apoptosis. Here, we report that activation of the CD95 pathway was involved in drug- and gamma-irradiation-induced apoptosis of medulloblastoma and glioblastoma cells. Upon treatment CD95 ligand (CD95-L) was induced that stimulated the CD95 pathway by crosslinking CD95 via an autocrine/paracrine loop. Blocking CD95-L/receptor interaction using F(ab')2 anti-CD95 antibody fragments strongly reduced apoptosis. Apoptosis depended on activation of caspases (interleukin 1beta-converting enzyme/Ced-3 like proteases) as it was almost completely abrograted by the broad range caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone. Apoptosis was mediated by cleavage of the receptor proximal caspase FLICE/MACH (caspase-8) and the downstream caspase CPP32 (caspase-3, Apopain) resulting in cleavage of the prototype caspase substrate PARP. Moreover, CD95 was upregulated in wild-type p53 cells thereby increasing responsiveness towards CD95 triggering. Since activation of the CD95 system upon treatment was also found in primary medulloblastoma cells ex vivo, these findings may have implications to define chemosensitivity and to develop novel therapeutic strategies in the management of malignant brain tumors.
Fulda
S
S
University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany.
Scaffidi
C
C
Pietsch
T
T
Krammer
P H
PH
Peter
M E
ME
Debatin
K M
KM
D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D001932:Brain Neoplasms; D053148:Caspase 3; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases / Q000378:metabolism; D002528:Cerebellar Neoplasms; D002588:Cesium Radioisotopes; D002945:Cisplatin / Q000633:toxicity*; D003513:Cycloheximide / Q000494:pharmacology; D004317:Doxorubicin / Q000633:toxicity*; D005434:Flow Cytometry; D005720:Gamma Rays; D005909:Glioblastoma; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D008527:Medulloblastoma; D018696:Neuroprotective Agents / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects
D000590:Amino Acid Chloromethyl Ketones; D002588:Cesium Radioisotopes; D007140:Immunoglobulin Fab Fragments; D018696:Neuroprotective Agents; C096713:benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; D019014:fas Receptor; D004317:Doxorubicin; D003513:Cycloheximide; C505407:CASP3 protein, human; C505530:CASP8 protein, human; C506433:CASP9 protein, human; D053148:Caspase 3; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases; D002945:Cisplatin